The Lower the ApoB, the Better: Now, How Does ApoB Fit in the Upcoming Era of Targeted Therapeutics?

El‐Shazly, Mohamed; Quispe, Renato

doi:10.1161/circulationaha.122.061188

Cited by 6 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cost–benefit analysis of incorporating an ApoB test into a traditional lipid panel analysis was not within the scope of this study. However, considering that ApoB has been suggested as a risk enhancer and therapeutic target for treatment in international guidelines, future studies should investigate the cost–benefit of the ApoB test along with its clinical utility [ 2 , 4 , 10 , 12 , 30 , 31 ].…”

Section: Discussionmentioning

confidence: 99%

Development and Validation of Multiple Equations for Low-Density Lipoprotein and Apolipoprotein B in Korean Patients Visiting Local Clinics and Hospitals

Choi

Lee

2023

Nutrients

View full text Add to dashboard Cite

We investigated the utilization of apolipoprotein B (ApoB), an independent risk factor for cardiovascular disease, and developed and validated a translational equation for calculating low-density lipoprotein cholesterol (LDL-C) in the Korean population visiting local clinics and hospitals. Among a total of 469,520 data sets of the lipid profile panel (total cholesterol, triglycerides, and high-density lipoprotein cholesterols), 142,932 lipid test sets with data on LDL-C and/or ApoB were used for statistical analysis. Using linear regression analysis, we created ApoB percentile value-derived LDL-C equations in a creating set and validated them with previously reported equations (a total of 11 equations) in comparison to directly measured LDL-C using two independent validating sets. Among all lipid test sets, the simultaneously measured ApoB test only accounted for 2.0%, indicating its underutilization in Korea. The ApoB-derived equations, which were derived in this study and previous studies, showed an overall agreement of ≥94.3% for NCEP ATP III criteria. However, the accuracy of the equations varied among data sets of populations. Future studies are needed to validate translational equations for ApoB and LDL-C in different populations to clarify the clinical implications of these equations.

show abstract

Section: Discussionmentioning

confidence: 99%

Development and Validation of Multiple Equations for Low-Density Lipoprotein and Apolipoprotein B in Korean Patients Visiting Local Clinics and Hospitals

Choi

Lee

2023

Nutrients

View full text Add to dashboard Cite

show abstract

“…Recognizing apoB is primarily responsible for cell recognition and LDL absorption. Therefore, despite of normal LDL levels, increased apoB suggests a high incidence rate of coronary heart disease [22].…”

Section: Apoa-1 31 Basic Information Of Apolipoproteinmentioning

confidence: 99%

Apolipoprotein A-1 in the treatment of acute myocardial infarction

Xue¹

2023

Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022)

View full text Add to dashboard Cite

With the gradual rejuvenation and rising popularity of acute myocardial infarction, more and more researchers have begun to investigate novel treatments for this disease. The treatment plan for continuing to increase high-density cholesterol based on apolipoprotein A-1 is gradually recognized by more and more people because of its theoretical and clinical practicability. However, there are relatively fewer experiments demonstrating the viability of apolipoprotein A-1 in clinical treatment compared to aspirin, ticlopidine, clopidogrel, and PTCA (percutaneous transluminal coronary angioplasty), which are mature technologies, and the summary of various clinical data is also far from sufficient. Therefore, apolipoprotein A-1 therapy is not widely used in the treatment of acute myocardial infarction yet. To fill this gap, this review will state the important clinical trials of apolipoprotein A-1 in treating acute myocardial infarction. in recent decades, summarize its clinical information, and analyze its proof of the feasibility for apolipoprotein therapy. Additionally, this review will assess the benefits and drawbacks of apolipoprotein A-1 therapy and currently available mature therapies (such as aspirin, ticlopidine and clopidogrel, PTCA). Therefore, it highlights the positive direction of apolipoprotein A-1 treatment and approaches in upcoming clinical experiments, assisting in apolipoprotein A-1 treatment's future rise to popularity.

show abstract

The Impact of Metabolic and Bariatric Surgery on Apo B100 Levels in Individuals with high BMI: A Multi-Centric Prospective Cohort Study

Jaliliyan,

Madankan,

Mosavari

et al. 2024

OBES SURG

View full text Add to dashboard Cite

The Lower the ApoB, the Better: Now, How Does ApoB Fit in the Upcoming Era of Targeted Therapeutics?

Cited by 6 publications

References 15 publications

Development and Validation of Multiple Equations for Low-Density Lipoprotein and Apolipoprotein B in Korean Patients Visiting Local Clinics and Hospitals

Development and Validation of Multiple Equations for Low-Density Lipoprotein and Apolipoprotein B in Korean Patients Visiting Local Clinics and Hospitals

Apolipoprotein A-1 in the treatment of acute myocardial infarction

The Impact of Metabolic and Bariatric Surgery on Apo B100 Levels in Individuals with high BMI: A Multi-Centric Prospective Cohort Study

Contact Info

Product

Resources

About